Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dova Aims For Accelerated Assessment In EU For Avatrombopag

Executive Summary

Will the European Medicines Agency decide this week that Dova Pharmaceuticals’ eventual marketing authorization application for avatrombopag should be fast-tracked? If it does, the potential new thrombocytopenia therapy would join just a handful of products that are being reviewed under the EMA’s accelerated assessment pathway.

Advertisement

Related Content

No Fast Route To EU Market For Dova's Avatrombopag
Dova’s Doptelet Gets First-To-Market Edge In Thrombocytopenia, Ahead Of Shionogi
Dova Keeps Mum On EU Fast-Track Request Outcome; Requests Well Down
New EMA Filings: Speedy Review For Lanadelumab But Cemiplimab Gets Standard Treatment
Two Hopefuls And A ‘No’: EMA Decisions On Accelerated Access
Appointments: Stada, Astellas, Novo Nordisk, Boehringer Ingelheim, Dova, Selvita, Orchard, MannKind, Cancer Genetics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel